Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ABT reported second quarter operating EPS of $0.52, which met the Street consensus and was 6.1% above its second
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury